Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05987228
Other study ID # 22/6/2022/2023
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 1, 2022
Est. completion date December 1, 2022

Study information

Verified date August 2023
Source The Hashemite University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Thymus vulgaris could potentially serve as a safer alternative to stimulant drugs for enhancing memory among university students. Furthermore, Thymus vulgaris may offer additional benefits in terms of reducing anxiety, depression, and improving sleep quality. However, it should be noted that the current research on the effects of orally administered Thymus vulgaris on the brain and nervous system is limited, and further studies are required to fully explore its potential advantages. Therefore, the purpose of this study is to investigate the effects of oral Thymus vulgaris on memory performance, anxiety, depression, and sleep quality in university students.


Description:

Thymus vulgaris belongs to the Lamiaceae family and is a flowering plant. It can be found worldwide, although its origin is in southern Europe [1]. This plant is characterized by its compact, bushy nature and evergreen shrub structure. Its leaves are small, gray-green, highly aromatic, and it produces clusters of purple or pink flowers [2]. Thymus vulgaris is commonly used as a spice to enhance the flavor of food. It is also utilized in the form of dietary supplements; such as capsules or essential oils [3]. Throughout history, Thymus vulgaris has been employed in folk medicine due to its remarkable antimicrobial and anti-inflammatory properties [4]. In Jordanian traditional medicine, it is frequently utilized as an antiseptic, bronchial, sedative, and spasmolytic agent, as well as to improve cognitive function and memory [5-8]. Numerous studies have reported various health benefits associated with Thymus vulgaris leaves, including antioxidant [9], diuretic [10], anti-inflammatory [11], antiviral [12], anti-cancerous [13], cholesterol-lowering [14], glucose-lowering [15], anticonvulsant [16], anti-anxiety [17] and sedative-hypnotic activities [18]. The primary constituents of Thymus vulgaris, notably thymol, p-cymene, γ-terpinene, linalool, and carvacrol, possess various neuropharmacological properties, including anti-anxiety, sedative, anticonvulsant, memory-enhancing, and anti-Alzheimer's disease effects [19]. Asadbegi et al. conducted a study demonstrating that thymol exhibited neuroprotective properties by reducing memory impairment caused by intrahippocampal injection of the amyloid beta (Aβ) peptide in rats fed a high-fat diet [20]. Furthermore, Capibaride et al. confirmed the significant antidepressant-like effect of thymol by observing its ability to reverse behaviors associated with chronic corticosterone exposure and decrease in BDNF levels in female mice [21]. Azizi et al. demonstrated that carvacrol and thymol exerted neuroprotective effects against Aβ25-35-induced damage, potentially through the attenuation of oxidative stress and the modulation of PKC activity, a protein associated with memory function [22]. Additionally, within the monoterpenes and sesquiterpenes, β-myrcene and caryophyllene have been identified as major compounds. β-myrcene is known for its analgesic, anxiolytic, and anti-inflammatory effects [23]. Multiple studies have highlighted the positive impact of Thymus vulgaris on memory, anxiety, and depression. Akan et al. conducted research on rats using the Morris water maze and found that Thymus vulgaris L. exhibited beneficial effects against diabetes mellitus-induced neuropathy and cognitive impairment [24]. They attributed these effects to specific components like thymol, carvacrol, 8-terpinene, p-cymene, and α-pinene present in high amounts in the essential oil composition. Similarly, Rabiei et al. suggested that Thymus vulgaris extract demonstrated anti-amnesic properties in rats with Sco-induced memory deficits, as assessed by the Morris water maze and passive avoidance tests [25]. The authors proposed that this effect could be linked to the extract's antioxidant activity or its influence on the cholinergic system, with carvacrol and thymol playing significant roles based on their chemical composition. Additionally, an ethanol extract derived from Thymus vulgaris leaves displayed an anxiolytic profile in rats during the EPM test, unaffected by locomotor activity [17]. Finally, in the context of Alzheimer's disease, a neurodegenerative disorder involving cholinergic neuron loss, administration of thyme oil to Caenorhabditis elegans enhanced neurotransmission by regulating synaptic acetylcholine levels [26]. The high prevalence of anxiety, depression, and sleep disorders among university students can significantly affect their memory function [27]. Consequently, an increasing number of university students have turned to using stimulant drugs to improve their memory performance and attention, despite the fact that such usage is unauthorized and not intended for therapeutic purposes [28]. However, the use of these drugs is associated with various side effects[29,30]. This has led neuroscience researchers to show a growing interest in identifying cognitive-enhancing drugs that can be safely used by healthy individuals without any detrimental effects. Based on the provided information, it is hypothesized that Thymus vulgaris could potentially serve as a safer alternative to stimulant drugs for enhancing memory among university students. Furthermore, Thymus vulgaris may offer additional benefits in terms of reducing anxiety, depression, and improving sleep quality. However, it should be noted that the current research on the effects of orally administered Thymus vulgaris on the brain and nervous system is limited, and further studies are required to fully explore its potential advantages. Therefore, the purpose of this study is to investigate the effects of oral Thymus vulgaris on memory performance, anxiety, depression, and sleep quality in university students.


Recruitment information / eligibility

Status Completed
Enrollment 86
Est. completion date December 1, 2022
Est. primary completion date December 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 23 Years
Eligibility Inclusion Criteria: - Health participants Exclusion Criteria: - individuals with medical diseases, psychiatric disorders, those using any medications (including complementary and alternative medicines), as well as pregnant and lactating individuals, were excluded from participating

Study Design


Intervention

Dietary Supplement:
Thymus vulgaris
500 mg of Thymus vulgaris (capsules) was given orally twice daily

Locations

Country Name City State
Jordan Faculty of Pharmaceutical Sciences Zarqa

Sponsors (1)

Lead Sponsor Collaborator
The Hashemite University

Country where clinical trial is conducted

Jordan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Memory performance Prospective and Retrospective Memory Questionnaire (PRMQ) was employed 30 days
Secondary Anxiety and depression Anxiety and depression levels were measured using the Hospital Anxiety and Depression Scale (HADS) 30 days
Secondary Sleep quality Pittsburgh Sleep Quality Inventory (PSQI) questionnaire was performed 30 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A